GRIN Therapeutics Funding: $140M Raised, Series D (2026)

GRIN Therapeutics is based in New York, New York. It has raised $140M in total funding. Latest round: Series D.

GRIN Therapeutics funding overview

GRIN Therapeutics is based in New York, New York. GRIN Therapeutics has raised $140M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series D announced in May 2026. The round record for GRIN Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include Angelini Pharma, Blackstone Life Sciences. 2 distinct backers are named across the disclosed rounds.

GRIN Therapeutics at a glance

Total raised
$140M
Latest round
Series D
Latest round date
May 2026
Headquarters
New York, New York
Notable investors
Angelini Pharma, Blackstone Life Sciences

Frequently asked about GRIN Therapeutics funding

How much has GRIN Therapeutics raised?
GRIN Therapeutics has raised $140M in total disclosed funding across the rounds on record.
Who has invested in GRIN Therapeutics?
Angelini Pharma, Blackstone Life Sciences are named among the investors backing GRIN Therapeutics.
What was the latest GRIN Therapeutics funding round?
The most recent disclosed round is a Series D, announced in May 2026.
Where is GRIN Therapeutics based?
GRIN Therapeutics is based in New York, New York.
When did GRIN Therapeutics last raise?
The last disclosed GRIN Therapeutics round closed in May 2026 at Series D.

Every GRIN Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in New York at a similar stage.

Companies related to GRIN Therapeutics (19)

Browse related funding lists (5)

Company funding database · Investor directory · Founder database · Mega-rounds 2026